{"status":"OK","data":{"advertisement":{"id":387726,"title":"REQUEST FOR QUOTATION No 22 09 2026 NG - Next Generation Sequencing (NGS) of PCR amplicon samples","partial_offer_allowed":false,"publication_date":"2026-09-22","submission_deadline":"2026-09-29 23:59:59","planned_sign_date":"2026-10-01","supplementary_orders":"VIII.3.\tW okresie realizacji Projektu, kt\u00f3ry na dzie\u0144 publikacji niniejszego zapytania ofertowego przewidziany jest do dnia 30.09.2028 r., Zamawiaj\u0105cy przewiduje mo\u017cliwo\u015b\u0107 udzielenia Wykonawcy wy\u0142onionemu w niniejszym post\u0119powaniu dodatkowych us\u0142ug nieobj\u0119tych zam\u00f3wieniem podstawowym, do wysoko\u015bci 50% warto\u015bci zam\u00f3wienia okre\u015blonej pierwotnie w umowie. Mo\u017cliwo\u015b\u0107 udzielania zam\u00f3wie\u0144 uzupe\u0142niaj\u0105cych stanowi element pierwotnych warunk\u00f3w realizacji umowy i zostanie przewidziana w umowie zawartej z Wykonawc\u0105. Zam\u00f3wienie uzupe\u0142niaj\u0105ce b\u0119dzie oznaczone jako \u201ezam\u00f3wienie uzupe\u0142niaj\u0105ce\u201d. Termin realizacji Projektu mo\u017ce ulec wyd\u0142u\u017ceniu w przypadku zmiany umowy o dofinansowanie Projektu.\n\nVIII.3.\tDuring the Project implementation period, which as of the date of publication of this RFQ is planned to continue until 30 September 2028, the Ordering Party reserves the right to award the Contractor selected in this procedure additional services not covered by the initial order, up to a maximum of 50% of the value of the original contract. The possibility of awarding such supplementary orders constitutes part of the original contractual conditions and will be included in the agreement concluded with the Contractor. Any such supplementary order will be designated as a \u201csupplementary order.\u201d\nThe Project implementation period may be extended in the event of an amendment to the Project funding agreement.","terms_of_contract_change":"Warunki zmiany umowy zosta\u0142y zamieszone w za\u0142\u0105czonym zapytaniu ofertowym w wersji PDF.\nThe terms and conditions of the contract amendment are set out in the attached PDF version of the RFQ.","created_at":"2026-09-22 17:48:57","modified_at":"2026-09-30 00:00:34","contact_persons":[{"id":57,"forename":"Aleksandra","surname":"Mazga\u0142a","phone_number":"+48 538 899 945","email":"tenders@ryvu.com","created_by":null,"created_at":"2026-11-06 17:43:17","modified_at":"2026-11-06 17:43:17","modified_by":null}],"orders":[{"id":628062,"estimated_value":null,"order_items":[{"id":706335,"description":"Sekwencjonowanie nowej generacji (NGS) pr\u00f3bek amplikon\u00f3w PCR:\n\nkontrola jako\u015bci materia\u0142u DNA; czysto\u015b\u0107 i integralno\u015b\u0107 DNA musz\u0105 zosta\u0107 zweryfikowane metod\u0105 elektroforezy w \u017celu agarozowym, a wyniki kontroli jako\u015bci powinny zosta\u0107 przedstawione w odr\u0119bnym raporcie przed rozpocz\u0119ciem dalszego przetwarzania pr\u00f3bek;\nprzygotowanie biblioteki sekwencyjnej bez etapu amplifikacji PCR (PCR-free);\nweryfikacja jako\u015bci biblioteki z wykorzystaniem ilo\u015bciowej reakcji PCR (qPCR) oraz ocena rozk\u0142adu d\u0142ugo\u015bci fragment\u00f3w;\nsekwencjonowanie przy u\u017cyciu wysokoprzepustowej platformy NGS opartej na technologii Sequencing by Synthesis (SBS) oraz technologii patternowanych kom\u00f3rek przep\u0142ywowych (patterned flow cells), generuj\u0105cej odczyty sparowane o d\u0142ugo\u015bci 150 pz (PE150) przy Q30 \u2265 85%, z mo\u017cliwo\u015bci\u0105 wyboru wydajno\u015bci sekwencjonowania wynosz\u0105cej 1,5 Gb, 15 Gb lub 30 Gb na bibliotek\u0119, zgodnie z wymaganiami dla poszczeg\u00f3lnych pr\u00f3bek;\nopracowanie raportu podsumowuj\u0105cego proces sekwencjonowania, zawieraj\u0105cego informacje o zastosowanej metodzie i przebiegu procesu, parametrach przebiegu sekwencjonowania oraz analizach statystycznych umo\u017cliwiaj\u0105cych ocen\u0119 jako\u015bci sekwencjonowania i pokrycia pr\u00f3bek;\nbioinformatyczna obr\u00f3bka danych obejmuj\u0105ca:\nkontrol\u0119 jako\u015bci wygenerowanych danych sekwencyjnych;\nfiltrowanie odczyt\u00f3w niskiej jako\u015bci oraz odczyt\u00f3w zawieraj\u0105cych sekwencje adapterowe;\nraportowanie parametr\u00f3w Q20 i Q30;\nanaliz\u0119 rozk\u0142adu wska\u017anika b\u0142\u0119d\u00f3w;\nanaliz\u0119 rozk\u0142adu zawarto\u015bci GC;\nbezpieczne przekazanie danych za po\u015brednictwem zabezpieczonej has\u0142em chmury obliczeniowej;\ndost\u0119p do chronionego has\u0142em konta online umo\u017cliwiaj\u0105cego monitorowanie bie\u017c\u0105cego statusu zam\u00f3wienia;\nregularna komunikacja dotycz\u0105ca post\u0119pu projektu i etap\u00f3w przetwarzania pr\u00f3bek za po\u015brednictwem dedykowanego kierownika projektu;\nzapewnienie wsparcia technicznego i obs\u0142ugi klienta przez ca\u0142y okres obowi\u0105zywania umowy.\n\nSzacowany zakres umowy: przygotowanie bibliotek sekwencyjnych - minimum 10 bibliotek, maksimum 100 bibliotek; sekwencjonowanie - minimum 100 Gb, maksimum 1000 Gb (g\u0142\u0119boko\u015b\u0107 sekwencjonowania).\n\nPowy\u017csze zakresy stanowi\u0105 minimalny i maksymalny wolumen zam\u00f3wie\u0144, kt\u00f3re mog\u0105 zosta\u0107 z\u0142o\u017cone przez Zamawiaj\u0105cego w ramach umowy. Zamawiaj\u0105cy nie jest zobowi\u0105zany do wykorzystania maksymalnego wolumenu wskazanego powy\u017cej, a Wykonawcy nie b\u0119d\u0105 przys\u0142ugiwa\u0107 \u017cadne roszczenia z tytu\u0142u z\u0142o\u017cenia zam\u00f3wie\u0144 o warto\u015bci lub wolumenie ni\u017cszym ni\u017c maksymalny okre\u015blony w umowie.\n\n***\n\nNext Generation Sequencing (NGS) of PCR amplicon samples: \n\uf0a7\tquality control of the DNA material; purity and integrity must be verified using agarose gel electrophoresis, with quality control results provided in a separate report prior to further sample processing;\n\uf0a7\tpreparation of a PCR-free sequencing library;\n\uf0a7\tverification of library quality using quantitative PCR (qPCR) and subsequent assessment of fragment length distribution;\n\uf0a7\tsequencing using a high-throughput next-generation sequencing platform based on Sequencing by Synthesis (SBS) technology and patterned flow cell technology, generating paired-end 150 bp reads (PE150) with Q30 \u2265 85%, with available sequencing output options of 1.5 Gb, 15 Gb, or 30 Gb per library, selectable according to the requirements of each sample;\n\uf0a7\tgeneration of a report summarizing the sequencing process, including information on the sequencing method and workflow, sequencing run parameters, and statistical analyses enabling assessment of sequencing quality and sample coverage;\n\uf0a7\tbioinformatic data processing including:\no\tquality control of generated sequencing data;\no\tfiltering of low-quality reads and reads containing adapter sequences;\no\treporting of Q20 and Q30 metrics;\no\terror rate distribution analysis;\no\tGC content distribution analysis;\n\uf0a7\tsecure, password-protected delivery of data via cloud-based storage;\n\uf0a7\taccess to a password-protected online account enabling tracking of current order status;\n\uf0a7\tregular communication regarding project progress and sample processing stages through a dedicated project manager;\n\uf0a7\tprovision of technical support and customer care throughout the contract period.\n\nEstimated scope of the contract: library preparation - minimum 10 libraries, maximum 100 libraries; sequencing - minimum 100 Gb, maximum 1000 Gb (sequencing depth). The above ranges constitute the minimum and maximum volume of orders that may be placed by the Ordering Party under the contract; the Contractor shall have no claim in respect of orders below the maximum volume.","warranty_period":null,"cpv_items":[{"id":8514,"code":"73110000-6","name":"Us\u0142ugi badawcze"}],"timetable_items":[],"fulfillment_places":[{"country":"Polska","voivodeship":"ma\u0142opolskie","poviat":"Krak\u00f3w","commune":"Krak\u00f3w-Podg\u00f3rze","locality":"Krak\u00f3w","created_by":null,"created_at":"2026-09-22 17:48:57","modified_at":"2026-09-22 17:48:57","modified_by":null,"id":804916,"type":{"id":1,"name":"adres"},"group_uuid":"7d544a0c-f899-4d2b-9640-9c602e7776be"}],"participation_conditions":[{"id":2021263,"description":"Pe\u0142na lista warunk\u00f3w udzia\u0142u w post\u0119powaniu znajduj\u0119 si\u0119 w za\u0142\u0105czonym zapytaniu ofertowym w wersji PDF.\n\nThe full list of conditions for participation in the proceedings can be found in the attached PDF version of the request for quotation.","type":{"id":6,"name":"Lista wymaganych dokument\u00f3w/o\u015bwiadcze\u0144"},"created_by":null,"created_at":"2026-09-22 17:48:57","modified_at":"2026-09-22 17:48:57","modified_by":null,"group_uuid":"32c9eb78-6591-4f1d-a513-ba2091c4aebd"}],"category":{"id":1,"name":"Us\u0142uga"},"subcategory":{"id":4,"name":"Us\u0142ugi badawcze"},"created_by":null,"created_at":"2026-09-22 17:48:57","modified_at":"2026-09-22 17:48:57","modified_by":null,"group_uuid":"67242876-fe99-44e7-9c53-7e533ea092dc"}],"evaluation_criteria":[{"id":1132974,"price_criterion":true,"description":"Cena Netto, Net Price (\"C\") - 100%","created_by":null,"created_at":"2026-09-22 17:48:57","modified_at":"2026-09-22 17:48:57","modified_by":null,"group_uuid":"9d28382e-797b-43fa-b167-db6fe933fc3c"}],"is_variant":false,"title":"NGS of PCR amplicon samples","order_node":{"id":473167},"created_by":null,"created_at":"2026-09-22 17:48:57","modified_at":"2026-09-22 17:48:57","modified_by":null}],"created_by":{"id":112,"contact_persons":[]},"modified_by":{"modified_by":null,"id":1,"contact_persons":[]},"status":{"id":2,"label":"PUBLISHED","name":"Opublikowane"},"advertiser_address_details":{"name":"RYVU THERAPEUTICS S.A.","identification_number_type":"nip","identification_number":"6792942955","address":{"country":"Polska","voivodeship":"ma\u0142opolskie","poviat":"Krak\u00f3w","commune":"Krak\u00f3w-Podg\u00f3rze","locality":"Krak\u00f3w","created_by":{"id":112,"contact_persons":[]},"created_at":"2026-09-22 17:48:57","modified_at":"2026-09-22 17:48:57","modified_by":{"id":112,"contact_persons":[]},"id":1099639,"street":"Sternbacha","number_description":"2","postcode":"30-394"},"created_by":{"id":112,"contact_persons":[]},"created_at":"2026-09-22 17:48:57","modified_at":"2026-09-22 17:48:57","modified_by":{"id":112,"contact_persons":[]},"id":388798},"advertisement":{"id":292611,"number":"2026-112-292611","publication_date":"2026-09-22","created_by":{"id":112,"contact_persons":[]},"created_at":"2026-09-22 17:10:16","modified_at":"2026-09-30 00:00:34","modified_by":{"modified_by":null,"id":1,"contact_persons":[]},"status":{"id":6,"label":"RESOLVED","name":"Rozstrzygni\u0119te"},"all_available_version_ids":[387722,387726],"enrollment":null,"projects":[{"id":46698,"name":"\"ONCO Prime: nowe mo\u017cliwo\u015bci personalizowanej terapii przeciwnowotworowej w oparciu o hodowl\u0119 kom\u00f3rek pierwotnych od pacjenta, charakteryzacj\u0119 omiczn\u0105 i testy funkcjonalne\"","number":"0095/23","activity":{"created_by":{"modified_by":null,"id":89,"contact_persons":[]},"created_at":"2023-02-01 09:22:25","modified_at":"2023-02-01 09:22:25","modified_by":{"modified_by":null,"id":89,"contact_persons":[]}},"region":null,"institution":{"created_by":{"modified_by":null,"id":89,"contact_persons":[]},"created_at":"2023-02-01 09:28:01","modified_at":"2023-02-01 09:28:01","modified_by":{"modified_by":null,"id":89,"contact_persons":[]}},"full_number":"FENG.01.01-IP.02-0095/23","perspective":{},"programme":{"created_by":{"modified_by":null,"id":89,"contact_persons":[]},"created_at":"2023-02-01 09:21:41","modified_at":"2023-02-01 09:21:41","modified_by":{"modified_by":null,"id":89,"contact_persons":[]}},"priority":{"created_by":{"modified_by":null,"id":89,"contact_persons":[]},"created_at":"2023-02-01 09:21:51","modified_at":"2023-02-01 09:21:51","modified_by":{"modified_by":null,"id":89,"contact_persons":[]}},"type":"project","created_by":{"id":112,"contact_persons":[]},"created_at":"2024-06-07 14:14:14","modified_at":"2024-06-07 14:14:14","modified_by":{"id":112,"contact_persons":[]}}],"is_author":false,"is_admin":false},"attachments":[{"origin":{"id":387726,"publication_date":"2026-09-22"},"id":2785675,"name":"RFQ 22 09 2026 NG.pdf","file":{"id":3091802,"name":"RFQ 22 09 2026 NG.pdf","created_at":"2026-09-22 17:48:48","created_by":{"forename":"Aleksandra","surname":"Mazga\u0142a"},"uri":"/api/files/3091802"},"group_uuid":"90bbb010-8705-4fff-a4bb-286d88de35cc"},{"origin":{"id":387726,"publication_date":"2026-09-22"},"id":2785676,"name":"Offer Form 22 09 2026 NG.docx","file":{"id":3091803,"name":"Offer Form 22 09 2026 NG.docx","created_at":"2026-09-22 17:48:53","created_by":{"forename":"Aleksandra","surname":"Mazga\u0142a"},"uri":"/api/files/3091803"},"group_uuid":"9e433415-4c28-443e-ab69-544ceaf41389"}]},"dictionaries":{"announcement_status_draft":1,"announcement_status_published":2},"favorite":null,"badge":null,"offer_set_badge_count":null,"question_badge_count":null}}